https://www.nabtrade.com.au/investor/insights/latest-news/news/2018/01/4_promising_biotechs
immutep is at the forefront of the approach of harnessing the immune system’s abilities as the future frontier of cancer treatment, with a particular focus on combination therapies. Major global pharmaceutical companies are backing LAG-3 as a meaningful therapeutic target, leaving IMM nicely positioned as the intellectual property owner.
And still we wait for this to reflect on the SH price!
https://www.nabtrade.com.au/investor/insights/latest-news/news/20...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
-0.020(6.56%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 28.5¢ | $913.3K | 3.099M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 124895 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 30287 | 2 |
View Market Depth
| Last trade - 16.10pm 21/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
